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EFFECTS OF VASOPRESSIN ON SWEAT RATE AND COMPOSITION IN 
PATIENTS WITH DIABETES INSIPIDUS AND NORMAL CONTROLS* 
LYNN M. TAUSSIG, M.D., AND GLENN D. BRAUNSTEIN, M.D.t 
ABSTRACT 
Baseline sweat rate and concentrations of sodium, chloride, and potassium, and the effect 
of exogenous vasopressin on these parameters were determined in 13 patients with acquired 
diabetes insipidus (ADI), four patients with nephrogenic diabetes insipidus (NDI), three 
subjects with cystic fibrosis, and age- and sex-matched controls. 
The four patients with NDI did not differ from the controls with respect to baseline sweat 
rate, but baseline sodium, chloride, and potassium concentrations were significantly 
elevated. In addition, parenteral vasopressin caused a significant decrease in sweat rate (p 
< .01) while the electrolyte concentrations remained unchanged. This indicates that 
vasopressin may also have an effect on electrolyte reabsorption in NDI patients. Alterna-
tively, the amount of sweat precursor fluid may have been reduced. 
The patients with ADI did not differ from the controls with respect to baseline data, and 
parenteral vasopressin had no effect on their sweat rate and composition. Likewise, 
vasopressin had no effect in controls or patients with cystic fibrosis. 
We conclude that, except in patients with NDI, vasopressin does not play a significant 
role in the regulation of human eccrine sweating. Sweat gland physiology appears to be 
different in patients with NDI and in them vasopressin may have a significant effect on 
sweat. 
Considerable controversy exists concerning the 
actions of antidiuretic hormone (ADH) on sweat 
rate and composition. While several studies [1-4] 
have demonstrated significant effects of exoge-
nous vasopressin on sweat, other investigators 
[5-12] have been unable to detect any such 
actions. Even the few studies [1-3] with positive 
results have differed from each other with respect 
to the observed effects of vasopressin on sweat. In 
an attempt to resolve some of these conflicts and 
to determine the role, if any, of ADH in sweat 
gland physiology, we studied sweat rate and 
electrolyte composition before and after the exoge-
nous administration of aqueous vasopressin in the 
following groups: (1) patients with acquired dia-
betes insipidus (ADI) who had severely decreased 
or absent endogenous ADH; (2) patients with ne-
phrogenic diabetes insipidus (NDI) with periph-
eral (renal) unresponsiveness to ADH; (3) patients 
with cystic fibrosis, a disease associated with 
abnormally elevated sweat electrolytes; and (4) 
normal controls. 
MATERIALS AND METHODS 
Thirteen patients, aged 7 to 28 years, with ADI due to 
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idiopathic causes ( 4 cases) or Hand-Schiiller-Christian 
disease (9 cases) and four patients with NDI, aged 8 to 28 
years, were studied; all NDI subjects and seven of the 13 
ADI patients were males. NDI was diagnosed as de-
scribed previously [13] for these same patients. Eight of 
the nine patients with Hand-Schiiller-Christian disease 
had concomitant growth hormone deficiency as an 
isolated anterior pituitary hormone defect (14]. Adrenal 
and thyroid function were normal in all patients with 
both forms of diabetes insipidus. The three patients with 
cystic fibrosis were 20, 26, and 28 years old with 
moderate to advanced disease; none had any history 
suggestive of ADH deficiency. Baseline sweat data on all 
patients were compared to results obtained from 36 age-
and sex-matched controls who had no history of signifi-
cant diseases and no family history of cystic fibrosis. All 
patients on vasopressin replacement had discontinued 
vasopressin tannate-in-oil for at least 48 hours and vaso-
pressin snuff and spray for 24 hours. Only one patient 
with NDI was taking medication and he discontinued 
the chlorthiazide and potassium therapy 4 days prior to 
testing. 
Sweating was stimulated by iontophoresis of a 0.2% 
pilocarpine nitrate solution according to a slight modifi-
cation of the method of Gibson and Cooke [15]. The sites 
for stimulation of sweating (in all cases the arms) were 
washed with distilled water and dried. Iontophoresis was 
performed for exactly 5 minutes at a current of 2 to 2.5 
rnA. After completion of the iontophoresis, the skin site 
was again washed with distilled water and dried. A piece 
of preweighed filter paper with extremely low sodium 
content (Whatman #44, Arthur H. Thomas Co., Phila-
delphia, Pa.) was placed on the area, covered with 
parafilm (previously washed in distilled water), and the 
edges sealed with tape to prevent evaporation. Sweating 
was allowed to proceed for exactly 45 minutes at which 
time the filter paper was rapidly removed, placed in a 
preweighed flask, and the weight of the sweat deter-
mined. The sweat was eluted from the filter paper with 
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distilled water. Sodium and potassium concentrations 
were determined by atomic absorption spectrophotome-
try (Perkin-Elmer 303, Perkin-Elmer Corp., Norwalk, 
Conn.) and chloride concentrations were determined 
with a chloridometer (Buchler-Cotlove, American In-
strument Co., Silver Spring, Md.). No sweat sample of 
less than 100 mg was accepted for study. 
All sweat collections were done in a cool environment 
(temperature of74 oF, relative humidity of30-50%) . The 
subjects were resting and were allowed fluids ad lib, 
although the amount ingested was not quantitated. All 
sweat tests were run in duplicate (i.e., for those subjects 
receiving vasopressin, 2 tests were done before giving the 
hormone and 2 after, all at different sites to prevent 
effects from the previous iontophoresis). 
At the conclusion of the control sweat tests, 5 units of 
aqueous vasopressin (Pitressin ®, [Parke, Davis, & Co., 
Detroit, Mich.]) were given intramuscularly to 12 of 13 
patients with ADI, all NDI patients, the three patients 
with cystic fibrosis , and five control subjects, aged 19 to 
21 years. The injection site was distant from the sweat 
collection areas. To determine whether the vasopressin 
had been absorbed from the injection site, a 60-minute 
sample of urine was collected before giving vasopressin 
for determination of volume, osmolarity, and concentra-
tions of sodium and chloride, and a similar sample was 
collected beginning one hour after vasopressin injection. 
The post-vasopressin sweat tests were started one hour 
after giving the vasopressin . Informed consent was 
obtained from all patients and there were no adverse 
effects from the tests. 
RESULTS 
Nephrogenic diabetes insipidus (NDI). The four 
patients with NDI did not differ significantly from 
normal controls with respect to baseline sweat 
rate (Table 1), but baseline sweat sodium concen-
trations were significantly elevated in all four 
patients when compared to age-matched normals 
(p < 0.01 and < 0.02 for the two age groups) and 
chloride concentrations were significantly higher 
(p < 0.02) in the two older patients with NDI; 
chloride concentrations in the younger NDI pa-
tients were not significantly higher (Table 1) . 
Potassium levels were significantly higher in the 
younger patients with NDI (p < 0.05) but were 
not measured in the two older patients (Table 1). 
Serum sodium levels in the two older patients 
with NDI were 148 and 151 mEq/1 and chloride 
levels were 109 and 111 mEq/1. 
Acquired diabetes insipidus (AD!). Comparing 
the baseline data from the 13 patients with ADI 
with age- and sex-matched controls, the only 
significant difference was the sweat rate for the 
patients 11 to 20 years of age . Otherwise, the 
patients with ADI did not differ significantly from 
the controls with respect to sweat rate and so-
dium, chloride, and potassium concentrations 
(Table I). Since baseline urine values for the ADI 
patients revealed very high volumes and low 
osmolarities, it is unlikely that any effects from 
previous therapy with vasopressin were still 
present at the time of testing. Serum electrolyte 
levels were normal. 
Effects of vasopressin . In all patients with ADI, 
the three patients with cystic fibrosis, and the 
control subjects, vasopressin had a marked renal 
effect as evidenced by a significant fall in urine 
volume and rise in osmolarity and concentrations 
of sodium and chloride. The NDI patients demon-
strated no renal response to the exogenous vaso-
pressin (Table II) . 
A significant decrease in sweat rate after vaso-
pressin administration was noted in all patients 
with NDI (p < 0.01); the sweat sodium, chloride, 
and potassium concentrations remained the same 
before and after vasopressin (Table III) in these 
four patients. Vasopressin had no effects on sweat 
rate and sweat sodium, chloride, and potassium 
concentrations in normal subjects, patients with 
ADI, and patients with cystic fibrosis (Table III). 
Sex had no influence in any group on any of the 
parameters studied. 
DISCUSSION 
Elevated sweat electrolytes previously have 
been reported in NDI, but the fe\Y patients de-
scribed were all under one year of age [16). It was 
suggested [16] that sweat analysis may aid in the 
diagnosis of NDI, but occasionally similarly ele-
vated values may be found in normals. Our 
findings of elevated baseline sodium, chloride, 
and potassium levels in the patients with NDI 
tend to confirm these previous reports and indi-
cate that the sweat abnormality in NDI may 
persist into adulthood. The increased baseline 
salinity of sweat in patients with NDI also sug-
gests that these patients, especially infants, may 
be at an increased risk of salt depletion, dehydra-
tion, and so-called heat prostration on exposure to 
excessive heat and exercise. A similar situation 
has been well described by di Sant'Agnese, Dar-
ling, Perera, and Shea [17] for cystic fibrosis, a 
disease with elevated sweat sodium and chloride 
concentrations. It is unclear why the baseline 
chloride values for the two younger NDI patients 
were not as elevated as they were for the two older 
patients; these results suggest that another anion, 
such as lactate, may appear in higher concentra-
tions in sweat in some of these patients. 
The patients with NDI also showed a significant 
decrease in sweat rate after receiving parenteral 
vasopressin but the sweat electrolyte concentra-
tions remained the same, indicating that vaso-
pressin also may have some effect on electrolyte 
reabsorption in the sweat ducts in these patients. 
Alternatively, the amount of sweat precursor fluid 
may have been reduced secondary to vasopressin-
induced vasoconstriction. If this second mecha-
nism is responsible for the changes noted, then 
this alone is of interest since the NDI patients 
were the only group to respond in such a drama-
tic manner; they decreased their mean sweat rate 
by 39 percent. Although we allowed our patients 
ad lib fluids we did not perform detailed water 
balance studies and therefore the patients with 
NDI,' who are usually in a state of chronic dehy-
Normals (5-10 years) 
Acquired Diabetes Insipidus (5-10 years) 
Normals (ll-20 years) 
Acquired Diabetes Insipidus (11-20 years) 
Normals (21-30 years) 
Acquired Diabetes Insipidus (21-30 years) 
Normals (5-10 years) 
Nephrogenic Diabetes Insipidus (5-10 years) 
Normals (21-30 years) 
Nephrogenic Diabetes Insipidus (21-30 years) 
* Mean ± standard error of the mean 
t Number of subjects in parentheses 
:j: N.S. = difference of means not significant 
§N.D. = not done 
TABLE I 
Baseline sweat rate and composition 
Sweat rate (gm/m'/45 min) Sodium (mEq/1) 
145.9 ± 55.2* (4)t (N S :j:) 16.8 ± 2.2 (6) 
88.6 ± 9.8 (3) . . 27 .7 ± 7.3 (3) (N .S.) 
113.2 ± 14.0 (14) ( 05) 30.3 ± 4.1 (15) 
68.1±11.5 (8) p< . 42.6 ± 6.8 (8) (N.S.) 
ll7.4 ± 15.9 (13) (N S) 
101.4 ± 51.0 (2) . . 
33.0 ± 3.3 (15) (N S ) 
53.7 ± 28.5 (2) .. 
145.9 ± 55 .2 (4) 16.8 ± 2.2 (6) 
115.8 ± 0.7 (2) (N.S.) 44.4±7.4 (2) (p <.01) 
ll7.4 ± 15.9 (13) (N S) 33.0 ± 3.3 (15) 
132.6 ± 10.4 (2) . . 57.9 ± 3.4 (2) (p <.02) 
Chloride (mEq/l) 
13.9 ± 3.7 (5) (N.S .) 
16.3 ± 4.4 (3) 
21.0 ± 2.4 (14) 
26.7 ± 5.6 (8) (N.S.) 
21.4 ± 2.8 (14) (N S ) 
41.5 ±27 .1 (2) . . 
13.9 ± 3.7 (5) 
30.8 ± 9.4 (2) (N.S.) 
21.4 ± 2.8 (14) 
42.0 ± 0.6 (2) (p <.02) 
-
~----
Potassium (mEq/l) 
7.1 ± 0.8 (6) (N .S.) 
7.9 ± 0.1 (2) 
7.8 ± 0.8 (12) (N S) 
10.4 ± 1.1 (8) . . 
N.D.§ 
7.1 ± 0.8 (6) 
11.6 ± 2.3 (2) (p < ·05) 
N.D. 
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TABLE II 
Urine findings before and after vasopressin 
Pre-Vasopressin Post-Vasopress in 
Grou p 
Acquired Di abetes Ins ipidus 
Nephrogen ic D ia betes Ins ipidus 
Cystic .Fibrois 
Normal Controls 
• All values in the table a re means 
t N. D. = not done 
Volume 
(cc) 
249* 
749 
87 
131 
Osmo- Sodium 
lari ty (mEq/L) 
176 29 
89 41 
647 107 
N. D.t 9 1 
TABLE Ill 
Potassium Volume Osmo-(mEq/L) (cc) larity 
36 67 558 
49 663 90 
153 55 810 
65 65 N.D .t 
Effects of vasopressin on sweat rat'e and composition 
N ormal Controls 
Rate (gm/ m'/45 min ) 
Sodium (mEq/1) 
Chloride (mEq/1) 
Potassium (mEq/1) 
Acquired Diabetes Insipidus 
Rate (gm/m '/45 min) 
Sod ium (mEq/1) 
Chloride (mEq/1) 
Potassium (mEq/1) 
Nephrogenic Diabetes Insipidus 
Rate (gm/m ' /45 min) 
Sodium (mEq/1) 
Chloride (mEq/ 1) 
Potassium (mEq/1) 
Cystic Fibrosis 
Rate (gm/ m '/45 min) 
Sodium (mEq/1) 
Chlor ide (mEq/1) 
Potassium (mEq/l) 
• Mean ± standa rd error of mean 
t Number of subjects in parentheses 
t N .S. = not signifi cant 
Pre-vasopressin 
107.5 ± 16.5* (5)'\' 
28.5 ± 4.6 (5) 
19.4 ± 4.2 (5) 
8.7 ± 0.3 (5) 
77.9 ± 10.0 (13) 
40.9 ± 5.9 (13) 
26.6 ± 5. I (13) 
9.4 ± 1.0 (11) 
124 .2 ± 6.4 (4) 
51.2 ± 5.1 (4) 
36.4 ;!, 5. 0 (4) 
11.6 ± 2.3 (2) 
122.5 ± 18.6 (3) 
96.8 ± 11.2 (3) 
101.4 ± 7.3 (3) 
15.1 ± 5.4 (3) 
Post -vasopressin 
106.0 11.2 (5) 
29.3 ± 4.8 (5) 
22.2 5.1 (5) 
7.7 ± 0.4 (5) 
82.4 ± 12.2 (12) 
41.3 ± 5.9 (12) 
27.9 ± 5.2 (12) 
9.8 ;!, 0.9 (10) 
76.3 ± 5.4 (4) 
50.1 4.7 (4) 
37.2 ± 3.9 (4) 
11.6 ± 2.6 (2) 
98.5 ± 20.7 (3) 
97.9 ± 11.5 (3) 
104.2 10.4 (3) 
14.2 ± 4.6 (3) 
Sod ium Potassium (mEq/L) (mEq/L) 
102 113 
15 23 
113 166 
163 130 
p va lues 
N.S. t 
N .S. 
N.S. 
N.S . 
N.S. 
N.S. 
N.S. 
N.S . 
< .01 
N.S. 
N.S. 
N.S. 
N.S. 
.s. 
N.S. 
N.S . 
dration and negative water balance, may have re-
mained in this condition during the tests. The 
high serum sodium and chloride levels in the two 
NDl patients in whom serum electrol ytes were 
measured indicate that this may have been the 
situation. Increased sweat water retent ion due to 
this dehydration or increased electrolyte secre-
t ion would seemingly be reasonabl e expl anations 
for the high base line swea t electrolyte concentra-
tions. However, dehydration would be expected 
to produce elevated leve ls of aldosterone which 
would lead to a decreased excretion of sweat so-
dium and chloride [18 ]. Dehydration also has 
been shown to cause a decrease in sweat rate [7]. 
The baselin e data for our NDI patients revealed 
the opposite: normal sweat rate and elevated ex-
cretion of electrolytes. lt is likewise difficult to 
postulate that an increased retention of water 
in the sweat ducts is due to the high endogenou 
vasopressin levels common in NDI [19) since the 
baseline sweat rates fo r t he NDI patients did not 
differ from normal. Thus, it is unclear at present 
why pat ients with NDI have higher baseline sweat 
electrolyte values and why exogenous vasopressin 
affects their sweat rate and sweat electrolyte con-
centralions. 
Our studies have demonstrated that patien ts 
who Jack ADH (ADI subjects) produce sweat at 
the same rate and with a s imi lar composition as 
normal subjects . The on ly sign ificant difference in 
the ADI subjects was the sweat rate for the age 
group 11- 20 years; this was an isolated findin g 
and we conclude that, as a group, the ADI 
patients did not differ significantly from the 
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control population. In addition , parentera l vaso-
pressin had no effect on sweat from ADI and cystic 
fibros is patients and cont rols. It should be noted 
that we measured gross sweat rate (i.e., rate over 
45 min) in cont rast to minute rates. It is poss ibl e 
that vasopress in has an effect on sweat stim ulated 
by iontophcresis during t he very early phases of 
sweating before t he sweat rate declines [20, 21). If 
this is t h e s it uat ion , then the vasopress in effects 
are only transient. We conclude t hat nor m ally 
vasopress in does not play a major role in the 
regulation of either pilocarpine-induced or physi-
ologic sweat ing. 
Our f indings of a lack of an effect of vaso press in 
on sweat in norm al situations a re similar to the 
resu lts from other studies. Lad ell [5] and Ladell 
an d Whitcher [8 ] found no effects of vasopress in 
on sweat rate as measured by loss of body weight 
in subjects exercis ing in moderate heat; Amatruda 
an d Welt [6] detected no differences in the rate of 
secretion and electrolyte composit ion of thermally 
induced sweat in two s ubj ects given vasopressin; 
and Pearcy, Robinson, Miller, Thomas, and De 
Brota [7] a lso found no difference in sweat ra te 
after vasopressin ad ministration to hydrated men 
working in the heat. Ratner and Dobson [9) could 
not demonstrate any change in sweat osmolari ty 
after giv ing vasopressin, and Cage and Dobson 
[10] noted no effects of 30 units of vasopressin on 
sweat sod ium excret ion and free water clearance 
in six normal men. Allen and Roddie [12] and 
Senay and van Beaumont [11] found no decrease 
in the rate of t herm ally induced sweat after 
vasopress in . 
Conversely , Hankiss [1] found a significant 
decrease in sweat rate but no cha nge in t he 
absolute value of sodium and potassium excretion 
in sweat after giving vasopress in to a patient with 
vasopressin-defic ient diabetes insipidus; t hey 
concluded that vaso press in h ad n o effect on sweat 
electrolyte excretion . In their study, sweat was 
collected from palms, and such sweat is known to 
be influenced by emotiona l stimuli . More re-
cently, Fasciolo, Tote! , and Johnson [2) demon-
strated t hat vasopress in given subdermally to hu -
mans s igni ficantly reduced sweat rate (measured 
over the vasopressin injection sites) and indepen -
dently st imulated t he active reabsorption of so-
dium. Quatrale and Speir [3 ] also noted that vaso-
pressin d ecreased the rate of sweat ing and sodium 
exc retion from t he footpads of the rat . It is diffi -
cult to compare a ll these in vest igat ions because 
of difference in the genera l designs of the stud-
ies, the methods of stimul at ing sweati ng, the coll -
ection of t h e sweat, and the amounts of vasopres-
sin used. 
We attempted to avoid t he effects of emotion, 
dehydration , heat, and exercise on endogenous 
ADH secretion and t he mechanism of sweati ng by 
using a s impl e, harm less technique (iontophore-
sis) on resting, hydrated subj ects in a controll ed , 
cool environment. It is unlikely that the normal 
subjects and patients with cystic fibros is had high 
endogenous se rum levels of ADH prior to testing. 
Local vasoconstrictive effects of vasopressin were 
minimized by giving t he hormone intramuscularly 
at sites distant from the sweat collection areas . 
Although the maximal effects of exogenous aque-
ous vasopressin may occur before one hour (the 
time at which we began our experimental set of 
sweat tests), act ivi ty h as been shown to last 3 to 4 
hours [22 ]. In addition , 1-hour urine samples 
collected during t he expe rimental sweat tests in 
ADI patients , cyst ic fibrosis patients , and normals 
revealed that t he vasopressin was sti ll having 
considerable renal act ion . 
We acknowledge with sincere appreciation the numer-
ous suggestions, advice, and comments made by Dr. 
Paul A. di Sant'Agnese. Also, we t hank Dr. Philip 
Gorden for referrin g his patients with diabetes insipidus 
to us and for his critical evaluation of the study and 
paper. 
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